NCT03011814 - Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 8, 2017

Primary Completion Date

June 23, 2026

Study Completion Date

August 30, 2026

Conditions

Folliculotropic Mycosis FungoidesRecurrent Cutaneous T-Cell Non-Hodgkin LymphomaRecurrent Mycosis FungoidesRefractory Cutaneous T-Cell Non-Hodgkin LymphomaRefractory Mycosis FungoidesRefractory Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedSezary SyndromeRecurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma

Interventions

BIOLOGICAL

Durvalumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Lenalidomide

Given PO

Trial Locations (4)

10065

Memorial Sloan-Kettering Cancer Center, New York

19107

Thomas Jefferson University Hospital, Philadelphia

77030

M D Anderson Cancer Center, Houston

91010

City of Hope Medical Center, Duarte

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER